Eli Lilly and Company has filed an 8-K to announce its financial results for the first quarter ended March 31, 2026. This disclosure is a critical event for investors as it provides the latest quarterly performance data necessary to assess the company's growth trajectory and financial health.

Eli Lilly and Company has released its financial results for the quarter and fiscal year ended December 31, 2025. This filing is a critical event for investors as it provides the official disclosure of the company's recent earnings and operational performance.

Eli Lilly and Company has released its financial results for the quarter ended September 30, 2025. This announcement provides the latest update on the company's operational performance and is a critical event for investors assessing the firm's growth trajectory and valuation.

Eli Lilly and Company has released its financial results for the quarter ended June 30, 2025. This announcement is a key event for investors as it provides the official update on the company's quarterly operational performance and financial condition.